Pharmacogenetic association of diabetes-associated genetic risk score with rapid progression of coronary artery calcification following treatment with HMG-CoA-reductase inhibitors -results of the Heinz Nixdorf Recall Study.

doi:10.1007/s00210-021-02100-7

Article

Pharmacogenetic association of diabetes-associated genetic risk score with rapid progression of coronary artery calcification following treatment with HMG-CoA-reductase inhibitors -results of the Heinz Nixdorf Recall Study.

Naunyn-Schmiedeberg's archives of pharmacology - 1 Aug 2021

Pechlivanis Sonali, Jung Dominik, Moebus Susanne, Lehmann Nils, Mahabadi Amir A, Hoffmann Per, Erbel Raimund, Nöthen Markus M, Bachmann Hagen S

Abstract excerpt

HMG-CoA-Reductase inhibitors (HMGRIs) are currently the most widely used group of drugs in patients with coronary artery disease (CAD) and are given preemptively to patients with high levels of cholesterol, including those with diabetes mellitus (DM). However, intake of HMGRIs also increases the progression of coronary artery calcification (CAC) and the risk of developing DM. This study aimed to investigate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Pharmacogenetic association of diabetes-associated genetic risk score with rapid progression of coronary artery calcification following treatment with HMG-CoA-reductase inhibitors -results of the Heinz Nixdorf Recall Study.

Abstract excerpt

Topics

Related research